Latest Breaking News On - Lee pasqualoni - Page 1 : comparemela.com

Johnson & Johnson : New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)

TITUSVILLE, NJ,March 5, 2023 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial. | March 5, 2023

United statesNew orleansMarcp bonacaKaitlin meiserLee pasqualoniMarc bonacaNone of the janssen pharmaceutical companiesDivision of cardiovascular medicineAmerican college of cardiologyUniversity of colorado anschutz medical campusJanssen pharmaceuticals incDrug administrationJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonExchange commissionCompanies of johnson

Johnson & Johnson : Real-World Study Confirms Benefit of XARELTO® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients

TITUSVILLE, NJ, December 9, 2022 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that. | December 9, 2022

United statesLee pasqualoniCraigi colemanAmerican heart associationJanssen pharmaceuticals incJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonCardiovascular metabolism at janssen scientific affairsUniversity of connecticutAmerican society of hematologyJanssen scientific affairsJanssenusand janssen scientific affairsNational blood clot allianceCenters for diseaseNone of the janssen pharmaceutical companiesSchool of pharmacy

Johnson & Johnson : FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD

Johnson & Johnson : FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesRyan goughMarcp bonacaJennifer mcintyreLee pasqualoniTraciec collinsWinta ghideiJennifer silventAmerican heart associationDivision of cardiovascular medicineJanssen pharmaceuticals incJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonClinical researchPartnership to advance cardiovascular health

Janssen Submits New Drug Application to U S FDA for XARELTO® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients

Janssen Submits New Drug Application to U S FDA for XARELTO® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

United kingdomJennifer mcintyreLee pasqualoniChristopher deloreficeSarah freemanNone of the janssen pharmaceutical companiesJanssen pharmaceuticals incJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonExchange commissionCompanies of johnsonJames listGlobal therapeutic area headJanssen researchJanssen pharmaceuticals

Late-Breaking Data at ACC 21 Show XARELTO® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization

Share this article Share this article RARITAN, N.J., May 16, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO ® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent event. The primary results of VOYAGER PAD showed that XARELTO ® plus aspirin reduced first events by 15 percent among patients with PAD after LER. This analysis showed a very high burden of subsequent events and a consistent 14 percent reduction in both primary endpoint events and total vascular events over a median of 2.5 years. These data were presented as a late-breaking presentation during the virtual American College of Cardiology s 70

United statesMarcp bonacaJennifer mcintyreLee pasqualoniChristopher deloreficeJennifer silventAmerican heart associationDivision of cardiovascular medicineJanssen pharmaceuticals incJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonJournal of the american college cardiologyClinical researchDepartment of medicineNone of the janssen pharmaceutical companies